PRIM1 Antibody

What is PRIM1 and why is it significant in cellular biology?

PRIM1 (DNA primase polypeptide 1) is the catalytic small subunit (49 kDa) of the DNA primase complex, which forms a critical component of the DNA polymerase alpha complex. This enzyme plays an essential role in DNA replication by synthesizing short RNA primers on both leading and lagging strands during DNA replication . During the S phase of the cell cycle, the DNA polymerase alpha complex (composed of catalytic subunit POLA1, accessory subunit POLA2, and two primase subunits - PRIM1 and PRIM2) is recruited to replicative forks via interactions with MCM10 and WDHD1 .

In the primase complex, both subunits are necessary for initial di-nucleotide formation, but primer extension depends primarily on the catalytic subunit (PRIM1). The protein synthesizes 9-mer RNA primers (also known as "unit length" RNA primers) and incorporates only ribonucleotides even when both ribo- and deoxy-nucleotide triphosphates are present . PRIM1 requires template thymine or cytidine to initiate RNA primer synthesis, with adenine or guanine at the 5'-end .

What types of PRIM1 antibodies are available for research, and how do they differ?

Research-grade PRIM1 antibodies are available in several formats with distinct characteristics:

The primary differences lie in the epitope recognition (where the antibody binds to PRIM1) and validation across different experimental applications and species .

How is PRIM1 protein typically detected in experimental settings?

PRIM1 protein detection employs several techniques:

• Western Blot (WB): Most commonly used for detecting PRIM1 at its expected molecular weight of approximately 50 kDa. Recommended dilutions range from 1:500 to 1:3000 depending on the specific antibody .

• Immunohistochemistry (IHC): Used for visualizing PRIM1 in tissue sections, typically with dilutions between 1:20 to 1:200. PRIM1 antibodies have been validated in human lymphoma tissue and thyroid cancer tissue .

• Immunofluorescence (IF)/Immunocytochemistry (ICC): Applied for cellular localization studies with dilutions between 1:50 to 1:500. Positive detection has been observed in HeLa cells .

• Immunoprecipitation (IP): Used to isolate and concentrate PRIM1 from complex protein mixtures, with recommended amounts of 0.5-4.0 μg antibody per 1.0-3.0 mg of total protein lysate .

For optimal results, experimental conditions should be titrated for each specific application and sample type .

How should researchers design validation experiments for new PRIM1 antibodies?

A rigorous validation approach for PRIM1 antibodies should include:

• Positive and negative control samples: Use cell lines with known PRIM1 expression (e.g., HeLa, Sp2/0, K-562, HepG2, Jurkat cells) as positive controls . For negative controls, consider PRIM1-knockdown cells generated via RNAi or CRISPR technology .

• Multiple detection methods: Validate the antibody across different applications (WB, IHC, IF) to ensure consistent results .

• Peptide competition assay: Use the immunizing peptide as a blocking peptide to confirm specificity. When pre-incubated with the antibody, the blocking peptide should prevent antibody binding to PRIM1 in your samples .

• Cross-reactivity assessment: Test reactivity across species if working with non-human models. Most PRIM1 antibodies show reactivity with human, mouse, and rat samples .

• Expression pattern consistency: Compare results with published literature regarding cellular localization, molecular weight, and expression patterns across different tissues .

This comprehensive validation strategy ensures reliable results in subsequent experiments with the antibody .

What are the optimal sample preparation methods for PRIM1 detection in different cell types?

Sample preparation methods vary by cell type and detection technique:

For Western Blot analysis:

• Extract total proteins using RIPA buffer supplemented with protease inhibitors.

• For hepatocellular carcinoma cells (BEL-7404, BCL-7402, HepG2, SMMC-7721), RNA extraction using Trizol followed by reverse transcription has shown good results for PRIM1 detection .

• Protein bands can be detected using enhanced chemiluminescence (Pierce ECL Substrate) and analyzed with Image J software .

For Immunohistochemistry:

• For human lymphoma or thyroid cancer tissue, antigen retrieval with TE buffer pH 9.0 is recommended. Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 .

• Optimal dilutions range from 1:20 to 1:200 depending on the antibody and tissue type .

For Immunofluorescence:

• For adherent cells like HeLa, fixation with 4% paraformaldehyde followed by permeabilization with 0.1% Triton X-100 works well .

• Recommended antibody dilutions range from 1:50 to 1:500 .

In all cases, the antibody should be titrated for optimal signal-to-noise ratio in each specific experimental system .

How can researchers quantify PRIM1 expression levels accurately?

Several methods provide accurate quantification of PRIM1 expression:

• qRT-PCR for mRNA quantification:

  • Total RNA isolation using Trizol followed by reverse transcription with Promega M-MLV.

  • GAPDH is commonly used as an internal control for normalization .

  • This method detected highest PRIM1 mRNA expression in BEL-7404 cells compared to BCL-7402, HepG2, and SMMC-7721 cell lines .

• Western blot densitometry for protein quantification:

  • After immunoblotting, use Image J software to measure band intensity.

  • Normalize to loading controls such as GAPDH or β-actin .

• FACS-based protein level assessment:

  • A FACS-based assay measuring PRIM1-GFP relative to a cotranslated RFP control can correct for cell-to-cell variation in transfection efficiency.

  • This approach ensures assessment of protein expression is not confounded by transcriptional differences or mRNA stability .

• Celigo imaging cytometer for proliferation studies:

  • This method can be used to assess the functional consequences of PRIM1 expression changes.

  • BEL-7404 and SMMC-7721 cells can be seeded (2000 cells/well) and incubated at 37°C in 5% CO2 for proliferation assessment .

Each method provides different insights into PRIM1 biology, with qRT-PCR offering mRNA-level information and Western blot/FACS providing protein-level data .

How is PRIM1 involved in cancer progression, particularly hepatocellular carcinoma?

PRIM1 has emerged as a significant factor in hepatocellular carcinoma (HCC) progression:

• Expression pattern in HCC: PRIM1 is significantly overexpressed in HCC tissues compared to normal liver tissues at both mRNA and protein levels. Analysis of RNA-seq data from 50 paired liver cancer samples from TCGA showed consistent upregulation .

• Prognostic value: High PRIM1 expression correlates with poor prognosis in HCC patients. This has been validated in TCGA, ICGC, and Nantong cohorts .

• Functional role in proliferation: Knockdown of PRIM1 via LV-PRIM1-RNAi in BEL-7404 and SMMC-7721 cells significantly reduces proliferative capacity as measured by Celigo imaging cytometer, Caspase3/7 Assay, flow cytometry, and MTT assay .

• In vivo tumor growth impact: PRIM1 knockdown results in decreased tumor weight and fluorescence intensity in xenograft models using SCID mice .

• Mechanistic insights: PRIM1 facilitates the epithelial-mesenchymal transition (EMT) process and activates the PI3K/AKT/mTOR signaling pathway in HCC cells. Additionally, PRIM1 can cause ubiquitination and degradation of P53 by upregulating Ubiquitin Conjugating Enzyme E2 C (UBE2C) .

These findings suggest PRIM1 functions as an oncogene in HCC, promoting proliferation and inhibiting apoptosis, making it a potential therapeutic target .

What role does PRIM1 play in genetic disorders and developmental processes?

PRIM1 has been implicated in several genetic disorders:

• Primordial dwarfism syndrome: Biallelic mutations in PRIM1 cause a distinctive form of primordial dwarfism. Using a variant classification agnostic approach, biallelic mutations in PRIM1 were identified in five individuals presenting with extreme growth failure .

• Molecular mechanisms in primordial dwarfism: PRIM1 protein levels were markedly reduced in patient cells, accompanied by replication fork asymmetry, increased interorigin distances, replication stress, and prolonged S-phase duration. These molecular defects led to impaired cell proliferation, explaining the patients' extreme growth failure .

• Other disorders: PRIM1 deficiency has also been associated with primary ovarian insufficiency and type 2 diabetes mellitus .

• Neurological implications: Missense mutations in PRIM1 can cause extensive apoptosis of retinal neurons through activation of the DNA damage checkpoint and tumor suppressor P53, without alterations in cell proliferation .

These findings highlight PRIM1's critical role in normal development through its function in DNA replication, with mutations causing phenotypic features distinct from those previously reported with DNA polymerase genes .

How can PRIM1 be targeted or manipulated for potential therapeutic applications?

Several approaches for targeting PRIM1 in therapeutic contexts have been investigated:

• RNA interference: LV-PRIM1-RNAi lentiviral vectors have successfully reduced PRIM1 expression in cancer cell lines. In BEL-7404 and SMMC-7721 cells, PRIM1 knockdown inhibited proliferation, induced apoptosis, and reduced tumor growth in xenograft models .

• Natural compounds: Inotilone isolated from Phellinus linteus has demonstrated anti-tumoral effects on PRIM1-expressing tumors. In vivo studies showed that administering inotilone (10 mg/kg, twice weekly for 6 weeks) significantly reduced BT-474-xenografted tumor growth volume compared to controls .

• Combination therapies: PRIM1 inactivation sensitizes colorectal cancer cells to ATR and CHK1 inhibitors, suggesting PRIM1 or other primase subunits could be novel targets for individualized tumor therapeutic approaches .

• Targeted drug development: Understanding PRIM1's role in the G2/M cell cycle checkpoint offers potential for developing targeted inhibitors that could disrupt cancer cell proliferation, particularly in estrogen receptor-positive breast cancers where PRIM1 is highly expressed .

For effective therapeutic targeting, careful consideration must be given to potential side effects, as PRIM1 is essential for normal DNA replication in all cells .

How can researchers address cross-reactivity concerns when using PRIM1 antibodies?

Cross-reactivity concerns with PRIM1 antibodies can be addressed through:

• Epitope selection and validation: High-quality antibodies are generated by choosing immunogens with maximum homology with target species but minimum homology among members of the same protein family. This is achieved through comprehensive sequence analysis before immunization and subsequent affinity purification on immobilized antigens .

• Multiple antibody approach: Use different antibodies targeting distinct epitopes of PRIM1 to confirm specificity. If multiple antibodies with different epitope recognition show consistent results, confidence in specificity increases .

• Knockout/knockdown controls: Generate PRIM1 knockdown or knockout cell lines using RNAi or CRISPR-Cas9 technology. These serve as negative controls to confirm antibody specificity. BEL-7404 and SMMC-7721 cell lines with PRIM1 knockdown have been successfully established and can serve as reference models .

• Blocking peptide experiments: Pre-incubate the antibody with excess immunizing peptide before application to samples. Signal elimination in this competitive binding assay confirms specificity to the target epitope .

• Western blot verification: PRIM1 has a well-defined molecular weight of approximately 50 kDa. Verification of a single band at this position supports antibody specificity .

By implementing these validation strategies, researchers can significantly reduce cross-reactivity concerns when using PRIM1 antibodies in their experiments .

What are the most effective strategies for studying PRIM1 interactions with other proteins in the replication complex?

Studying PRIM1's interactions with other proteins in the replication complex can be approached through:

• Co-immunoprecipitation (Co-IP): PRIM1 antibodies can be used for immunoprecipitation from cell lysates (recommended: 0.5-4.0 μg antibody for 1.0-3.0 mg total protein lysate), followed by Western blot analysis for potential interacting partners like POLA1, POLA2, and PRIM2 . Positive IP has been successfully detected in HeLa cells .

• Proximity ligation assay (PLA): This technique detects protein-protein interactions in situ with high sensitivity by generating fluorescent signals only when two proteins are in close proximity (<40 nm).

• FRET/BRET analysis: For studying dynamic interactions, Förster Resonance Energy Transfer (FRET) or Bioluminescence Resonance Energy Transfer (BRET) can be used by tagging PRIM1 and potential interacting partners with appropriate fluorophores or luciferase.

• Yeast two-hybrid screening: This can identify novel interaction partners of PRIM1 within the replication complex.

• Mass spectrometry following IP: After immunoprecipitating PRIM1, mass spectrometry analysis can identify the complete interactome of PRIM1 in different cellular contexts.

• ChIP-seq analysis: To study PRIM1 interactions with chromatin and DNA, Chromatin Immunoprecipitation followed by sequencing can map PRIM1 binding sites across the genome.

The LinkedOmics database (http://www.linkedomics.org/login.php) can be used to predict the functions and pathways modulated by PRIM1 through over-representation enrichment analysis (ORA), providing computational insights to guide experimental approaches .

What technical challenges might arise when studying PRIM1 in primordial dwarfism patient samples, and how can they be overcome?

Studying PRIM1 in primordial dwarfism patient samples presents several technical challenges:

• Limited sample availability: Primordial dwarfism is rare, with only five individuals with biallelic PRIM1 mutations identified in previous research .

  • Solution: Establish patient-derived cell lines or use CRISPR-Cas9 to introduce patient-specific mutations into standard cell lines for mechanistic studies.

• Complex phenotype interpretation: PRIM1 mutations show phenotypic features distinct from those previously reported with DNA polymerase genes .

  • Solution: Comprehensive phenotypic characterization with correlation to molecular defects through multi-omics approaches.

• Variant interpretation: Some pathogenic variants may be in non-coding regions, making their identification challenging .

  • Solution: Use variant classification agnostic approaches as successfully employed by Parry et al., who identified homozygous intronic variants (c.638+36C>G) in PRIM1 .

• Functional validation of hypomorphic alleles: PRIM1 is essential for cellular survival, so disease-causing mutations are necessarily hypomorphic alleles .

  • Solution: Develop sensitive functional assays like the FACS-based assay that measures PRIM1-GFP levels relative to cotranslated RFP control, which successfully quantified the effect of the C301R substitution (25 ± 0.3% protein level) .

• Complex replication phenotypes: PRIM1 deficiency causes replication fork asymmetry, increased interorigin distances, and replication stress .

  • Solution: Employ techniques like DNA fiber analysis to visualize replication dynamics and γH2AX staining to assess replication stress.

By addressing these challenges with appropriate methodological approaches, researchers can gain valuable insights into the role of PRIM1 in normal development and disease pathogenesis .

How should researchers interpret conflicting data between mRNA and protein expression levels of PRIM1?

When faced with discrepancies between PRIM1 mRNA and protein expression levels, researchers should consider:

• Post-transcriptional regulation: PRIM1 may be subject to microRNA regulation or RNA binding proteins that affect translation efficiency without changing mRNA levels.

  • Analysis approach: Investigate the 3'UTR of PRIM1 for miRNA binding sites and examine correlations between PRIM1 protein levels and expression of potential regulatory RNAs.

• Post-translational modifications: PRIM1 protein stability or activity may be regulated through ubiquitination, phosphorylation, or other modifications.

  • Analysis approach: The study by Wei et al. showed PRIM1 could cause ubiquitination and degradation of P53 by upregulating UBE2C . Similar mechanisms might regulate PRIM1 itself.

• Protein degradation pathways: Differences in proteasomal or lysosomal degradation rates could explain discrepancies.

  • Analysis approach: Treat cells with proteasome inhibitors (e.g., MG132) or lysosome inhibitors (e.g., chloroquine) to assess PRIM1 protein stability.

• Technical considerations:

  • Different detection sensitivities between qRT-PCR and Western blot.

  • Antibody epitope accessibility issues affecting protein detection.

  • Different normalization standards for mRNA (often GAPDH) versus protein (often β-actin).

  • Analysis approach: Use multiple antibodies targeting different epitopes and multiple reference genes for normalization.

• Cell cycle effects: As a DNA replication protein, PRIM1 levels may fluctuate during the cell cycle.

  • Analysis approach: Synchronize cells and measure both mRNA and protein levels at defined cell cycle stages.

What are the emerging roles of PRIM1 beyond DNA replication that researchers should investigate?

Recent findings suggest several non-canonical roles of PRIM1 worth investigating:

• Signal transduction pathway modulation: PRIM1 has been shown to activate the PI3K/AKT/mTOR signaling pathway in HCC cells, suggesting roles beyond DNA replication .

• Epithelial-mesenchymal transition (EMT) regulation: PRIM1 facilitates the EMT process in HCC cells, indicating potential functions in cellular differentiation and tissue organization .

• P53 pathway interaction: PRIM1 can cause ubiquitination and degradation of P53 by upregulating UBE2C, suggesting a role in regulating cell cycle checkpoints and apoptosis beyond its primary replication function .

• Developmental regulation: The distinctive primordial dwarfism syndrome associated with PRIM1 mutations shows phenotypic features different from those observed with DNA polymerase gene mutations, suggesting unique developmental functions .

• Metabolic influences: PRIM1 deficiency has been linked to type 2 diabetes mellitus, suggesting potential roles in metabolic regulation .

• Hormone responsiveness: PRIM1 appears to be involved in estrogen-induced breast cancer formation, indicating hormone-responsive functions that warrant further investigation .

• Cell cycle regulation beyond S-phase: PRIM1's involvement in G2/M cell cycle checkpoint activation suggests broader cell cycle regulatory functions .

These emerging roles represent frontier areas for PRIM1 research beyond its established DNA replication functions .

How might single-cell sequencing technologies enhance our understanding of PRIM1 function in heterogeneous tissues?

Single-cell sequencing technologies offer several advantages for studying PRIM1 function:

• Cell-type specific expression patterns: Single-cell RNA sequencing (scRNA-seq) can reveal differential expression of PRIM1 across cell types within heterogeneous tissues like liver or breast tumors, providing insights into cell populations where PRIM1 might play crucial roles .

• Cell cycle phase resolution: Since PRIM1 functions in DNA replication, single-cell approaches can correlate PRIM1 expression with cell cycle phases at unprecedented resolution, revealing potential regulatory mechanisms .

• Clonal evolution in tumors: Single-cell DNA sequencing can track how PRIM1 alterations contribute to tumor heterogeneity and clonal evolution in cancers where PRIM1 is implicated, such as HCC and breast cancer .

• Spatial context integration: Spatial transcriptomics can map PRIM1 expression within tissue architecture, revealing microenvironmental influences on PRIM1 function.

• Multi-omics integration: Combining single-cell transcriptomics, proteomics, and epigenomics can provide comprehensive insights into PRIM1 regulation and function.

• Rare cell population detection: In developmental disorders like primordial dwarfism associated with PRIM1 mutations, single-cell approaches can identify rare cell populations particularly affected by PRIM1 dysfunction .

These technologies could greatly enhance our understanding of how PRIM1 contributes to both normal development and disease pathogenesis across different tissue contexts .

What are the most promising approaches for targeting PRIM1 in cancer therapy based on current research?

Based on current research, several promising approaches for targeting PRIM1 in cancer therapy emerge:

• RNA interference therapeutics: Lentiviral-mediated PRIM1 knockdown has shown efficacy in reducing tumor growth in HCC and breast cancer models . Advanced RNA interference delivery systems could translate this approach to clinical applications.

• Small molecule inhibitors: Developing specific inhibitors targeting PRIM1's catalytic activity could disrupt cancer cell replication. This approach would be particularly relevant for cancers with PRIM1 overexpression like HCC and estrogen receptor-positive breast cancers .

• Natural product derivatives: Inotilone from Phellinus linteus demonstrated significant anti-tumoral effects against PRIM1-expressing tumors in vivo (10 mg/kg, twice weekly for 6 weeks) . Further development of natural product derivatives could yield clinically viable compounds.

• Synthetic lethality approaches: PRIM1 inactivation sensitizes colorectal cancer cells to ATR and CHK1 inhibitors . Expanding this concept to identify additional synthetic lethal interactions could lead to effective combination therapies.

• Targeting PRIM1-dependent signaling pathways: Since PRIM1 activates PI3K/AKT/mTOR signaling in HCC cells, combining PRIM1 inhibition with existing PI3K/AKT/mTOR inhibitors might enhance therapeutic efficacy .

• Immunotherapy combinations: Exploring how PRIM1 inhibition affects tumor immunogenicity could lead to rational combinations with immune checkpoint inhibitors.

• Biomarker-guided therapy: High PRIM1 expression correlates with poor survival in several cancers . Using PRIM1 as a biomarker could guide patient selection for targeted therapies.

Each approach has specific advantages and challenges, with RNA interference and small molecule inhibitor development currently showing the most promising preclinical evidence .

What are the optimal storage conditions for maintaining PRIM1 antibody activity?

Optimal storage conditions for PRIM1 antibodies:

• Temperature requirements: Store at -20°C for long-term storage. PRIM1 antibodies are stable for one year after shipment when stored properly at this temperature .

• Formulation considerations: Most commercial PRIM1 antibodies are provided in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3, which helps maintain stability during freeze-thaw cycles .

• Aliquoting recommendations: Aliquoting is generally unnecessary for -20°C storage of glycerol-containing formulations, but for antibodies without glycerol or for highly valuable stocks, dividing into small aliquots minimizes freeze-thaw cycles .

• Short-term storage: For frequent use, store at 4°C for up to one month to avoid repeated freeze-thaw cycles that can damage antibody structure and function .

• Reconstitution considerations: For lyophilized antibodies, briefly centrifuge the vial before opening to ensure all material is at the bottom. Reconstitute in double-distilled water or other appropriate diluent as specified by the manufacturer .

• Handling precautions: Avoid repeated freeze-thaw cycles as this can significantly reduce antibody activity. Upon thawing, briefly centrifuge the vial to collect all liquid at the bottom .

Following these storage guidelines will help maintain PRIM1 antibody reactivity and specificity for extended periods .

What controls should be included when designing experiments with PRIM1 antibodies to ensure result validity?

A comprehensive control strategy for PRIM1 antibody experiments should include:

Basic Controls:

• Positive Control: Include samples known to express PRIM1, such as HeLa, Sp2/0, K-562, HepG2, or Jurkat cells for Western blot applications .

• Negative Control:

  • Primary antibody omission control to assess background from secondary antibody

  • Isotype control (rabbit IgG for most PRIM1 antibodies) to assess non-specific binding

  • PRIM1 knockdown or knockout cells when available

Advanced Controls:

• Blocking Peptide Control: Pre-incubate the PRIM1 antibody with excess immunizing peptide before application to samples. Signal elimination confirms specificity to the target epitope .

• Multiple Antibody Validation: Use different antibodies targeting distinct PRIM1 epitopes to confirm specificity (e.g., combining C-terminal targeting antibody like ab230693 with others) .

• Expression Level Controls: When studying altered PRIM1 expression, include samples with known differential expression (e.g., normal liver tissue vs. HCC tissue) .

• Loading Controls: For Western blots, include appropriate loading controls such as GAPDH, β-actin, or total protein staining methods .

• Cross-species Validation: If working across species, include samples from each species to confirm cross-reactivity claims .

• Cell Cycle Controls: Since PRIM1 function is cell cycle-dependent, synchronize cells at different cell cycle phases to validate expression patterns .